Overview
- Allogene shares climbed more than 41% after Monday's interim ALPHA3 readout showed 58.3% minimal residual disease (MRD) negativity with cema‑cel versus 16.7% with observation.
- Treated patients had no cytokine release syndrome or neurotoxicity and no treatment‑related serious events in the early dataset.
- The trial tests cema‑cel as first‑line consolidation guided by Natera’s CLARITY MRD assay, which finds high‑risk patients before clinical relapse.
- Baird raised its price target to $9 and lifted its program success odds to 70%, while Jefferies set a $6 Buy and Citizens kept Market Outperform at $5.
- The study plans to enroll about 220 patients across 60‑plus sites with efficacy endpoints still blinded, an event‑free survival look planned in 2027, and primary results expected in 2028.